EPIX vs. CALT, DAWN, ABCL, MIRM, PRTA, COLL, ELVN, SAVA, ARCT, and IRWD
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Cassava Sciences (SAVA), Arcturus Therapeutics (ARCT), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
ESSA Pharma has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.
ESSA Pharma received 322 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 76.37% of users gave ESSA Pharma an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Calliditas Therapeutics AB (publ) currently has a consensus price target of $35.00, suggesting a potential downside of 12.48%. ESSA Pharma has a consensus price target of $16.50, suggesting a potential upside of 144.44%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Calliditas Therapeutics AB (publ).
2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 14.7% of ESSA Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ESSA Pharma has a net margin of 0.00% compared to ESSA Pharma's net margin of -40.19%. Calliditas Therapeutics AB (publ)'s return on equity of -19.46% beat ESSA Pharma's return on equity.
In the previous week, Calliditas Therapeutics AB (publ) had 26 more articles in the media than ESSA Pharma. MarketBeat recorded 32 mentions for Calliditas Therapeutics AB (publ) and 6 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 0.12 beat Calliditas Therapeutics AB (publ)'s score of 0.03 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media.
Summary
ESSA Pharma beats Calliditas Therapeutics AB (publ) on 14 of the 17 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
